Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEL-212 in Symptomatic Gout and Hyperuricemia
NCT02959918Phase 2Completed
- Sponsor
- Selecta Biosciences
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
A Phase 2 trial of SEL-212 in gout, hyperuricemia, sponsored by Selecta Biosciences. Started Oct 2016; status: completed.
02
Drugs
SEL-212
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02959918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959918.